1
|
Mejía-Manzano LA, Campos-García VR, Perdomo-Abúndez FC, Medina-Rivero E, González-Valdez J. Mono-PEGylated lysozyme purification with increased productivity and isomer differentiation through heparin monolith chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2022; 1204:123323. [PMID: 35700648 DOI: 10.1016/j.jchromb.2022.123323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 05/25/2022] [Accepted: 06/03/2022] [Indexed: 11/18/2022]
Abstract
PEGylated protein purification with the required quality attributes has represented a bioengineering challenge and Affinity Monolith Chromatography (AMC) has never been exploited for this goal. This work reports the generation of a heparin-modified affinity monolith disk by reductive alkylation with raised ligand density for its use as chromatographic support in the separation of lysozyme PEGylation reactions (LPRs) with three different PEG sizes (1, 20 and 40 kDa). For immobilized heparin determination a modified toluidine colorimetric assay adapted to microplate format was proposed. The heparin modified-disk was able to differentiate positional isomers of 20 kDa mono-PEGylated lysozyme at neutral pH using a salt linear gradient. Identity of PEG-conjugates was verified by SDS-PAGE and positional isomers were partially characterized by peptide mapping mass spectrometry. 20 kDa mono-PEGylated lysozyme conjugate purity (99.69 ± 0.05%) was comparable with traditional chromatographic methods while productivity (0.0964 ± 0.0001 mg/mL*min) was increased up to 6.1 times compared to that obtained in heparin packed-bed affinity chromatography procedures. The proposed AMC method represents a reliable, efficient, easy-handling, fast and single-step operation for the analysis or preparative isolation of PEGylated proteins containing a heparin binding domain.
Collapse
Affiliation(s)
- Luis Alberto Mejía-Manzano
- Tecnologico de Monterrey, School of Engineering and Science, Av. Eugenio Garza Sada 2501 Sur, Monterrey, NL, Mexico
| | - Víctor R Campos-García
- Tecnologico de Monterrey, School of Engineering and Science, Av. Eugenio Garza Sada 2501 Sur, Monterrey, NL, Mexico
| | - Francisco C Perdomo-Abúndez
- Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, Mexico
| | - Emilio Medina-Rivero
- Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, Mexico
| | - José González-Valdez
- Tecnologico de Monterrey, School of Engineering and Science, Av. Eugenio Garza Sada 2501 Sur, Monterrey, NL, Mexico.
| |
Collapse
|
2
|
Chitramuthu BP, Campos-García VR, Bateman A. Multiple Molecular Pathways Are Influenced by Progranulin in a Neuronal Cell Model-A Parallel Omics Approach. Front Neurosci 2022; 15:775391. [PMID: 35095393 PMCID: PMC8791029 DOI: 10.3389/fnins.2021.775391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 12/13/2021] [Indexed: 11/13/2022] Open
Abstract
Progranulin (PGRN) is critical in supporting a healthy CNS. Its haploinsufficiency results in frontotemporal dementia, while in experimental models of age-related neurodegenerative diseases, the targeted expression of PGRN greatly slows the onset of disease phenotypes. Nevertheless, much remains unclear about how PGRN affects its target cells. In previous studies we found that PGRN showed a remarkable ability to support the survival of NSC-34 motor neuron cells under conditions that would otherwise lead to their apoptosis. Here we used the same model to investigate other phenotypes of PGRN expression in NSC-34 cells. PGRN significantly influenced morphological differentiation, resulting in cells with enlarged cell bodies and extended projections. At a molecular level this correlated with pathways associated with the cytoskeleton and synaptic differentiation. Depletion of PGRN led to increased expression of several neurotrophic receptors, which may represent a homeostatic mechanism to compensate for loss of neurotrophic support from PGRN. The exception was RET, a neurotrophic tyrosine receptor kinase, which, when PGRN levels are high, shows increased expression and enhanced tyrosine phosphorylation. Other receptor tyrosine kinases also showed higher tyrosine phosphorylation when PGRN was elevated, suggesting a generalized enhancement of receptor activity. PGRN was found to bind to multiple plasma membrane proteins, including RET, as well as proteins in the ER/Golgi apparatus/lysosome pathway. Understanding how these various pathways contribute to PGRN action may provide routes toward improving neuroprotective therapies.
Collapse
Affiliation(s)
- Babykumari P Chitramuthu
- Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, and Centre for Translational Biology, Metabolic Disorders and Complications, McGill University Health Centre Research Institute, Montréal, QC, Canada
| | - Víctor R Campos-García
- Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, and Centre for Translational Biology, Metabolic Disorders and Complications, McGill University Health Centre Research Institute, Montréal, QC, Canada
| | - Andrew Bateman
- Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, and Centre for Translational Biology, Metabolic Disorders and Complications, McGill University Health Centre Research Institute, Montréal, QC, Canada
| |
Collapse
|
4
|
Campos-García VR, Herrera-Fernández D, Espinosa-de la Garza CE, González G, Vallejo-Castillo L, Avila S, Muñoz-García L, Medina-Rivero E, Pérez NO, Gracia-Mora I, Pérez-Tapia SM, Salazar-Ceballos R, Pavón L, Flores-Ortiz LF. Process signatures in glatiramer acetate synthesis: structural and functional relationships. Sci Rep 2017; 7:12125. [PMID: 28935954 PMCID: PMC5608765 DOI: 10.1038/s41598-017-12416-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Accepted: 09/04/2017] [Indexed: 12/14/2022] Open
Abstract
Glatiramer Acetate (GA) is an immunomodulatory medicine approved for the treatment of multiple sclerosis, whose mechanisms of action are yet to be fully elucidated. GA is comprised of a complex mixture of polypeptides with different amino acid sequences and structures. The lack of sensible information about physicochemical characteristics of GA has contributed to its comprehensiveness complexity. Consequently, an unambiguous determination of distinctive attributes that define GA is of highest relevance towards dissecting its identity. Herein we conducted a study of characteristic GA heterogeneities throughout its manufacturing process (process signatures), revealing a strong impact of critical process parameters (CPPs) on the reactivity of amino acid precursors; reaction initiation and polymerization velocities; and peptide solubility, susceptibility to hydrolysis, and size-exclusion properties. Further, distinctive GA heterogeneities were correlated to defined immunological and toxicological profiles, revealing that GA possesses a unique repertoire of active constituents (epitopes) responsible of its immunological responses, whose modification lead to altered profiles. This novel approach established CPPs influence on intact GA peptide mixture, whose physicochemical identity cannot longer rely on reduced properties (based on complete or partial GA degradation), providing advanced knowledge on GA structural and functional relationships to ensure a consistent manufacturing of safe and effective products.
Collapse
Affiliation(s)
- Víctor R Campos-García
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V., Cruce de Carreteras Acatzingo-Zumpahuacán s/n, Colonia Los Shiperes, Tenancingo, 52400, Estado de México, Mexico
| | - Daniel Herrera-Fernández
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V., Cruce de Carreteras Acatzingo-Zumpahuacán s/n, Colonia Los Shiperes, Tenancingo, 52400, Estado de México, Mexico
| | - Carlos E Espinosa-de la Garza
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V., Cruce de Carreteras Acatzingo-Zumpahuacán s/n, Colonia Los Shiperes, Tenancingo, 52400, Estado de México, Mexico
| | - German González
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V., Cruce de Carreteras Acatzingo-Zumpahuacán s/n, Colonia Los Shiperes, Tenancingo, 52400, Estado de México, Mexico
| | - Luis Vallejo-Castillo
- Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala s/n, Colonia Santo Tomás, 11340, Ciudad de México, Mexico.,Departamento de Farmacología, Cinvestav-IPN, Avenida Instituto Politécnico Nacional 2508, Colonia San Pedro Zacatenco, 07360, Ciudad de México, Mexico
| | - Sandra Avila
- Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala s/n, Colonia Santo Tomás, 11340, Ciudad de México, Mexico
| | - Leslie Muñoz-García
- Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala s/n, Colonia Santo Tomás, 11340, Ciudad de México, Mexico
| | - Emilio Medina-Rivero
- Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala s/n, Colonia Santo Tomás, 11340, Ciudad de México, Mexico
| | - Néstor O Pérez
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V., Cruce de Carreteras Acatzingo-Zumpahuacán s/n, Colonia Los Shiperes, Tenancingo, 52400, Estado de México, Mexico
| | - Isabel Gracia-Mora
- Departamento de Quı́mica Inorgánica y Nuclear, Facultad de Quı́mica, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, Investigación Científica 70, 04510, Ciudad de México, Mexico
| | - Sonia Mayra Pérez-Tapia
- Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala s/n, Colonia Santo Tomás, 11340, Ciudad de México, Mexico.,Unidad de Investigación, Desarrollo e Innovación Médica y Biotecnológica (UDIMEB), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala s/n, Colonia Santo Tomás, 11340, Ciudad de México, Mexico
| | - Rodolfo Salazar-Ceballos
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V., Cruce de Carreteras Acatzingo-Zumpahuacán s/n, Colonia Los Shiperes, Tenancingo, 52400, Estado de México, Mexico
| | - Lenin Pavón
- Laboratorio de Psicoinmunología, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente, Calzada México-Xochimilco 101, Colonia San Lorenzo Huipulco, 14370, Ciudad de México, Mexico
| | - Luis F Flores-Ortiz
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V., Cruce de Carreteras Acatzingo-Zumpahuacán s/n, Colonia Los Shiperes, Tenancingo, 52400, Estado de México, Mexico.
| |
Collapse
|
5
|
Campos-García VR, López-Morales CA, Benites-Zaragoza E, Jiménez-Miranda A, Espinosa-de la Garza CE, Herrera-Fernández D, Padilla-Calderón J, Pérez NO, Flores-Ortiz LF, Medina-Rivero E. Design of a strong cation exchange methodology for the evaluation of charge heterogeneity in glatiramer acetate. J Pharm Biomed Anal 2016; 132:133-140. [PMID: 27721069 DOI: 10.1016/j.jpba.2016.10.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Revised: 09/27/2016] [Accepted: 10/02/2016] [Indexed: 11/16/2022]
Abstract
Complex pharmaceuticals are in demand of competent analytical methods able to analyze charge heterogeneity as a critical quality attribute (CQA), in compliance with current regulatory expectations. A notorious example is glatiramer acetate (GA), a complex polypeptide mixture useful for the treatment of relapsing-remitting multiple sclerosis. This pharmaceutical challenges the current state of analytical technology in terms of the capacity to study their constituent species. Thus, a strong cation exchange methodology was designed under the lifecycle approach to support the establishment of GA identity, trough the evaluation of its chromatographic profile, which acts as a charge heterogeneity fingerprint. In this regard, a maximum relative margin of error of 5% for relative retention time and symmetry factor were proposed for the analytical target profile. The methodology met the proposed requirements after precision and specificity tests results, the former comprised of sensitivity and selectivity. Subsequently, method validation was conducted and showed that the method is able to differentiate between intact GA and heterogeneity profiles coming from stressed, fractioned or process-modified samples. In summary, these results provide evidence that the method is adequate to assess charge heterogeneity as a CQA of this complex pharmaceutical.
Collapse
Affiliation(s)
- Víctor R Campos-García
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán s/n, Tenancingo, Mexico
| | - Carlos A López-Morales
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán s/n, Tenancingo, Mexico
| | - Eleuterio Benites-Zaragoza
- Unidad de Calidad, Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán s/n, Tenancingo, Mexico
| | - Armando Jiménez-Miranda
- Unidad de Calidad, Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán s/n, Tenancingo, Mexico
| | - Carlos E Espinosa-de la Garza
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán s/n, Tenancingo, Mexico
| | - Daniel Herrera-Fernández
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán s/n, Tenancingo, Mexico
| | - Jesús Padilla-Calderón
- Unidad de Calidad, Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán s/n, Tenancingo, Mexico
| | - Néstor O Pérez
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán s/n, Tenancingo, Mexico
| | - Luis F Flores-Ortiz
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán s/n, Tenancingo, Mexico.
| | - E Medina-Rivero
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán s/n, Tenancingo, Mexico.
| |
Collapse
|
6
|
Affiliation(s)
| | | | | | - Néstor O. Pérez
- a Unidad de Investigación y Desarrollo , Tenancingo , Estado de México , México
| | | |
Collapse
|
7
|
Espinosa-de la Garza CE, Perdomo-Abúndez FC, Campos-García VR, Pérez NO, Flores-Ortiz LF, Medina-Rivero E. Capillary gel electrophoresis for the quantification and purity determination of recombinant proteins in inclusion bodies. Electrophoresis 2013; 34:2754-9. [PMID: 23857606 DOI: 10.1002/elps.201300232] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2013] [Revised: 05/28/2013] [Accepted: 06/04/2013] [Indexed: 02/05/2023]
Abstract
In this work, a high-resolution CGE method for quantification and purity determination of recombinant proteins was developed, involving a single-component inclusion bodies (IBs) solubilization solution. Different recombinant proteins expressed as IBs were used to show method capabilities, using recombinant interferon-β 1b as the model protein for method validation. Method linearity was verified in the range from 0.05 to 0.40 mg/mL and a determination coefficient (r(2) ) of 0.99 was obtained. The LOQs and LODs were 0.018 and 0.006 mg/mL, respectively. RSD for protein content repeatability test was 2.29%. In addition, RSD for protein purity repeatability test was 4.24%. Method accuracy was higher than 90%. Specificity was confirmed, as the method was able to separate recombinant interferon-β 1b monomer from other aggregates and impurities. Sample content and purity was demonstrated to be stable for up to 48 h. Overall, this method is suitable for the analysis of recombinant proteins in IBs according to the attributes established on the International Conference for Harmonization guidelines.
Collapse
|